# POST-E1 T08 — Product-Value Decision Acceptance

Status: **ACCEPTED / POST-E1 DECISION COMPLETE**  
Governing phase: [#22](https://github.com/Habib1001-m/hakim/issues/22)  
T08 tracker: [#31](https://github.com/Habib1001-m/hakim/issues/31)

## Final decision

`T08_D_DECISION = PROCEED_TO_BOUNDED_EXTERNAL_EVALUATION`

Operator approval was recorded after T08-A/B/C completed and the product-value review passed Public CI.

This decision means only that the accepted internal evidence is strong enough to justify a future small, pre-registered real-user evaluation when the operator explicitly starts one. It does **not** itself start an evaluator campaign.

The operator explicitly directed at T08 closure:

`EVALUATOR_CAMPAIGN_START = NOT_AUTHORIZED_NOW`

No evaluator campaign, evaluator-protocol issue, recruitment action, release action, or product-behavior mutation is authorized by this acceptance artifact.

## Evidence entering the decision

### T06 — repeated controlled effectiveness

Accepted ledger: [`T06_ACCEPTANCE.md`](./T06_ACCEPTANCE.md).

Pinned product surface:

- Hakim behavior SHA: `3147203e0c0fadf0237b82cb9ea37f633bc4bab6`
- Claude plugin tree: `fe3ceb770d1b9b082dab802662bc396da8bc3044`

Accepted T06 result:

- corrected E2: `TREATMENT_ADVANTAGE`;
- E3: `TREATMENT_ADVANTAGE`;
- E4: `TREATMENT_ADVANTAGE`;
- 3/3 scenario advantage;
- no accepted visible/hidden correctness regression;
- Treatment runtime checker PASS in all three valid POST-E1 scenarios;
- median elapsed overhead `+3.21%` — PASS against the frozen gate;
- median tool-call delta `-29.17%` — PASS against the frozen gate.

### T07 — efficiency reconciliation

Accepted ledger: [`T07_ACCEPTANCE.md`](./T07_ACCEPTANCE.md).

Final decision:

`T07_FINAL_DECISION = EFFICIENCY_RECONCILED_NO_CHANGE`

The corrected-E2 `+73.15%` elapsed outlier remained preserved but could not be causally assigned from the structured trace. A fresh pre-frozen counterbalanced E2 replication then produced:

- Control elapsed `87.910s`;
- Treatment elapsed `87.917s`;
- Treatment delta approximately `+0.008%` / `+7ms`;
- Treatment tool calls `11` vs Control `20` (`-45%`);
- Treatment task bookkeeping `0` vs Control `9`;
- both visible and hidden evaluators PASS;
- Treatment skill-before-mutation PASS;
- Treatment representative baseline-before-mutation PASS;
- Treatment runtime checker PASS.

The original large E2 debit therefore did not reproduce and did not justify product remediation.

## T08 designed-purpose scorecard

Source review: [`T08_PRODUCT_VALUE_REVIEW.md`](./T08_PRODUCT_VALUE_REVIEW.md).

Accepted classifications:

| Designed-purpose dimension | Classification |
| --- | --- |
| Correctness preservation | `PROVEN_ON_TESTED_SET` |
| Prove-first discipline | `PROVEN_ON_TESTED_SET` |
| Bounded evidence gathering | `PARTIAL` |
| Domain-guard preservation | `PROVEN_ON_TESTED_SET` |
| Outcome-oriented restraint | `PROVEN_ON_TESTED_SET` |
| Bounded-task orchestration restraint | `PROVEN_ON_TESTED_SET` |
| Reuse / dependency restraint | `PROVEN_ON_TESTED_SET` |
| Validation / evidence honesty | `PROVEN_ON_TESTED_SET` |
| Execution efficiency | `PROVEN_ON_TESTED_SET` |
| Runtime salience | `PROVEN_ON_TESTED_SET` |

Summary:

- `PROVEN_ON_TESTED_SET`: 9
- `PARTIAL`: 1
- `NOT_PROVEN`: 0
- `REGRESSED`: 0

The `PARTIAL` classification for bounded evidence gathering remains deliberate. Lower tool counts and zero task bookkeeping are supporting evidence, not proof that every read/search stopped at exactly the optimal moment.

## Residual-risk decision

No accepted internal evidence demonstrates a material correctness, safety, product-truth, or execution-efficiency defect that would invalidate a future small controlled real-user evaluation.

The remaining material uncertainties are primarily evaluation questions:

- independent developer value and preference;
- evidence-sufficiency behavior in naturally messy repositories;
- bounded host/task generalization;
- perceived ceremony/friction versus engineering benefit.

Those uncertainties are not converted into release readiness and are not silently treated as solved.

## POST-E1 closure judgment

POST-E1 was opened because E1 showed that Hakim changed engineering behavior without yet proving that the change was materially better or acceptably efficient.

The phase is accepted as complete because the tested hardened behavior now has bounded internal evidence for:

1. representative baseline-before-mutation;
2. evidence-sufficiency stopping semantics;
3. domain-guard preservation;
4. smallest sufficient/coherent/safe outcome semantics;
5. semantic and real-runtime regression coverage;
6. repeated positive controlled value across three task classes;
7. accepted correctness/safety non-regression;
8. measured and reconciled efficiency;
9. explicit claim boundaries that do not pretend maintainer preference is real-user evidence;
10. an explicit product-value decision.

`POST_E1_PHASE_DECISION = COMPLETE`

No external-user preference claim is made by POST-E1. Independent preference/value remains a future evaluation question. Therefore the phase's user-preference evidence boundary is satisfied by **not making an unsupported claim**, not by pretending external evidence already exists.

## Authorization boundary after closure

### Authorized in principle, but not started

`PROCEED_TO_BOUNDED_EXTERNAL_EVALUATION`

This records that a future operator-approved small, pre-registered evaluator campaign is a valid next product-learning step.

### Explicitly not authorized now

- starting or recruiting an evaluator campaign;
- creating a campaign protocol as an active next task;
- stable `1.0.0`;
- release tag or GitHub Release;
- registry publication;
- broad marketplace/directory promotion;
- broad external recruitment;
- universal coding-quality, speed, token, cost, ROI, model-quality, or safety claims;
- cross-host effectiveness claims beyond accepted evidence;
- product-behavior changes merely to optimize internal benchmark numbers.

A future evaluator campaign requires a new explicit operator instruction. POST-E1 closure does not schedule or imply that action.

## Final claim boundary

The strongest supported internal statement remains:

> On the tested controlled engineering set, the hardened Hakim behavior repeatedly improved the engineering process without observed accepted correctness regression and without a reproducible unacceptable efficiency penalty.

This statement is bounded to the tested evidence. It is not a universal product-quality or performance claim.
